<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02883439</url>
  </required_header>
  <id_info>
    <org_study_id>2015-002865-40</org_study_id>
    <nct_id>NCT02883439</nct_id>
  </id_info>
  <brief_title>Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate</brief_title>
  <acronym>BIODYMF</acronym>
  <official_title>Open Label Two -Treatment Half Side Comparative Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasoen Propionate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate and to compare the bioavailability of MP29-02 and&#xD;
      fluticasone propionate in nasal tissue after nasal application. This may provide a rational&#xD;
      basis for the use of 1 puff per nostril dosage regimen of the drugs. Clinical experience has&#xD;
      demonstrated the efficacy of the twice-daily treatment; however, so far, no data are&#xD;
      available on the local tissue concentrations of MP29-02 after topical application.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a single-centre, two-treatment half-side comparative open-label trial; all&#xD;
      subjects will receive DymistaÂ® or Flixonase Aqua in one nostril each.&#xD;
&#xD;
      Nasal tissue samples will be obtained from 24 patients. Subjects will be selected based on&#xD;
      the subjects plan to undergo septoplasty, septorhinoplasty, or functional endoscopic sinus&#xD;
      surgery. Subjects with different diagnoses can be added in the study: non-allergic rhinitis,&#xD;
      allergic rhinits, chronic sinusitis and nasal polyposis. The number of subjects is based on a&#xD;
      previous experiment where the presence of fluticasone propionate was tested on human nasal&#xD;
      mucosal surface and in human nasal tissue after nasal application (Bonsmann, 2001).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no available patients&#xD;
  </why_stopped>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bioavailability of MP29-02 in human nasal mucosa compared to commercially available fluticasone propionate</measure>
    <time_frame>1 hour</time_frame>
    <description>bioavailability of both medicines will be tested in nasal mucosa and nasal secretion 1 after application</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Bioavailability Study</condition>
  <arm_group>
    <arm_group_label>Investigational product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MP29-02 137</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-investigational product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fluticasone propionate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP29-02</intervention_name>
    <description>local nasal application</description>
    <arm_group_label>Investigational product</arm_group_label>
    <other_name>Dymista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate</intervention_name>
    <description>local nasal application</description>
    <arm_group_label>Non-investigational product</arm_group_label>
    <other_name>FP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Male and female patients&#xD;
&#xD;
          -  Age: 18 - 70 years (included)&#xD;
&#xD;
          -  Subjects who need to undergo septoplasty, septorhinoplasty or functional endoscopic&#xD;
             sinus surgery unrelated to this study&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Patients who are member of the staff or relatives thereof directly involved in the&#xD;
             conduct of the protocol&#xD;
&#xD;
          -  Participant in any other trial during the last 30 days&#xD;
&#xD;
          -  Previous treatment with Dymista or any other topical corticosteroid spray or drops&#xD;
             within the last month before the operation&#xD;
&#xD;
          -  Previous treatment with systemic corticosteroid in the last 2 months before operation&#xD;
&#xD;
          -  Previous treatment with anti-histaminics 7 days before operation&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Allergic for one of the compounds azelastinehydrochloride or fluticasonpropionate&#xD;
&#xD;
          -  Significant co-morbidity (for instance, but not limited to):&#xD;
&#xD;
               -  Glaucoma, cataracts, and increased intraocular pressure.&#xD;
&#xD;
               -  Subjects with active or quiescent tuberculosis; fungal, bacterial, viral, or&#xD;
                  parasitic infections; or ocular herpes simplex&#xD;
&#xD;
               -  Subjects with severe liver disease&#xD;
&#xD;
          -  Use of prohibited concomitant medication&#xD;
&#xD;
               -  Potent inhibitors of cytochrome P450 (CYP) 3A4&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
          -  Patients unwilling or unable to attend the proposed visit schedule&#xD;
&#xD;
          -  Patients suspected or known not to be trustworthy or who are likely not to comply with&#xD;
             the study directives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Bachert</last_name>
    <role>Principal Investigator</role>
    <affiliation>Upper Airways Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent University Hospital, Ghent, Belgium.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ghent, departement otorhinolaryngology</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MP29-02</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

